TITLE

Optimal vaccination to prevent pneumococcal disease?

AUTHOR(S)
Plosker, Greg
PUB. DATE
November 2012
SOURCE
PharmacoEconomics & Outcomes News;11/24/2012, Issue 667, p5
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article focuses on several studies related to 13-valent pneumococcal conjugate vaccine (PCV13) for invasive pneumococcal disease (IPD). Researchers in Malaysia have found that the said vaccine can lessen the burden of the disease. Studies in Brazil also show the potential of PCV13 compared to PCV10 and no vaccination of high-risk children. A budget impact analysis reveals the cost-effectiveness of 23-valent pneumococcal polysaccharide vaccine (PPV23).
ACCESSION #
84039952

 

Related Articles

  • Impact of routine PCV7 (Prevenar) vaccination of infants on the clinical and economic burden of pneumococcal disease in Malaysia.  // BMC Infectious Diseases;2011, Vol. 11 Issue 1, p248 

    The article presents information on a study conducted to estimate the clinical and economic burden of pneumococcal disease in Malaysia, and to assess the cost effectiveness of routine infant vaccination with PCV7. In the study, a decision model was used that focused on disease burden, treatment...

  • Immune Response to Pneumococcal Conjugate and Polysaccharide Vaccines in Otitis-Prone and Otitis-Free Children. Barnett, Elizabeth D.; Pelton, Stephen I.; Cabral, Howard J.; Eavey, Roland D.; Allen, Carole; Cunningham, Michael J.; McNamara, Eileen R.; Klein, Jerome O. // Clinical Infectious Diseases;7/1/99, Vol. 29 Issue 1, p191 

    Provides information on a study which compared responses to the pneumococcal conjugate vaccine (PCV) and pneumococcal polysaccharide vaccine to understand the roles of vaccines in the prevention of pneumococcal disease including otitis media. How the study was conducted; Results; Discussion of...

  • Protecting against invasive pneumococcal disease: Be wise--immunize! Squires, Susan G.; Spika, John S. // CMAJ: Canadian Medical Association Journal;10/06/98, Vol. 159 Issue 7, p826 

    Discusses invasive pneumococcal pneumonia. Characteristics; Treatment choices; Recommendations from the Canadian Immunization Guide; Introduction of pneumococcal vaccination programs for high-risk groups in Canada.

  • PCV-13 "borderline" cost effective in England.  // PharmacoEconomics & Outcomes News;11/10/2012, Issue 666, p4 

    The article discusses research on the cost effectiveness of pneumococcal 13-valent CRM197 vaccine conjugate (PCV-13). It references the study "The cost-effectiveness of a 13-valent pneumococcal conjugate vaccination for infants in England," by A. J. van Hoek et al. It also notes the article...

  • Cost-effectiveness of pneumococcal conjugate vaccination in Latin America and the Caribbean: a regional analysis. Anushua Sinha; Constenla, Dagna; Valencia, Juan Esteban; O'Loughlin, Rosalyn; Gomez, Elizabeth; de la Hoz, Fernando; Valenzuela, Maria Teresa; de Quadros, Ciro A. // Revista Panamericana de Salud Publica;Nov2008, Vol. 24 Issue 5, p304 

    Objective. In Latin America and the Caribbean, routine vaccination of infants against Streptococcus pneumoniae would need substantial investment by governments and donor organizations. Policymakers need information about the projected health benefits, costs, and cost-effectiveness of vaccination...

  • Estimating the cost-effectiveness of pneumococcal conjugate vaccination in Brazil. Vespa, Glaucia; Constenla, Dagna O.; Pepe, Camila; Safadi, Marco Aurélio; Berezin, Eitan; de Moraes, José Cássio; de Campos, Carlos Alberto Herrerias; Araujo, Denizar Vianna; de Andrade, Ana Lucia S. S. // Revista Panamericana de Salud Publica;Dec2009, Vol. 26 Issue 6, p518 

    Objective. To compare the costs and benefits of pneumococcal conjugate vaccination compared with no vaccination from the perspectives of the health care system and society. Methods. Using data from established sources, we estimated the incidence and mortality due to invasive pneumococcal...

  • Herd immunity confers added cost benefit for pneumococcal vax.  // PharmacoEconomics & Outcomes News;3/26/2005, Issue 474, p10 

    Discusses research being done on the effect of herd immunity on the cost effectiveness of pneumococcal 7-valent conjugate vaccine in Great Britain. Reference to a study by P. Conway et al, published in the February 25, 2005 issue of the "Vaccine" journal; Number of deaths that could be...

  • Response to the cost effectiveness analysis of pneumococcal conjugated vaccines in Peru. Gomez, Jorge A.; Castrejón, Maria M.; Van de Velde, Nicolas // Journal of Infection in Developing Countries;Jul2015, Vol. 9 Issue 7, p796 

    No abstract available.

  • Assessment of Health Benefits and Cost-Effectiveness of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccination in Kenyan Children. Ayieko, Philip; Griffiths, Ulla K.; Ndiritu, Moses; Moisi, Jennifer; Mugoya, Isaac K.; Kamau, Tatu; English, Mike; Scott, J. Anthony G. // PLoS ONE;Jun2013, Vol. 8 Issue 6, p1 

    Background: The GAVI Alliance supported10-valent pneumococcal conjugate vaccine (PCV10) introduction in Kenya. We estimated the cost-effectiveness of introducing either PCV10 or the13-valent vaccine (PCV13) from a societal perspective and explored the incremental impact of including indirect...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics